PL1695965T3 - Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne - Google Patents

Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne

Info

Publication number: PL1695965T3
Authority: PL; Poland
Prior art keywords: pharamcetuical; ivabradine; chlorhydrate; preparation; composition containing
Prior art date: 2005-02-28

Application number

PL06290326T

Other languages

English (en)

Inventor

Stéphane Horvath

Marie-Noëlle Auguste

Gérard DAMIEN

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-28

Filing date

2006-02-28

Publication date

2009-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1695965(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-28 Application filed by Servier Lab filed Critical Servier Lab

2009-01-30 Publication of PL1695965T3 publication Critical patent/PL1695965T3/pl

Links

ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title 1
229960003825 ivabradine Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
- D21H27/10—Packing paper
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
- B65D85/30—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H21/00—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
- D21H21/14—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
- D21H21/16—Sizing or water-repelling agents
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
- D21H27/30—Multi-ply
- D21H27/40—Multi-ply at least one of the sheets being non-planar, e.g. crêped

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Mechanical Engineering (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Plural Heterocyclic Compounds (AREA)

PL06290326T 2005-02-28 2006-02-28 Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne PL1695965T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0501985A FR2882553B1 (fr)	2005-02-28	2005-02-28	Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP06290326A EP1695965B9 (fr)	2005-02-28	2006-02-28	Forme cristalline beta du chlorhydrate de l'ivabradine, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number	Publication Date
PL1695965T3 true PL1695965T3 (pl)	2009-01-30

Family

ID=34954954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06290326T PL1695965T3 (pl)	2005-02-28	2006-02-28	Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne

Country Status (42)

Country	Link
US (3)	US7361649B2 (pl)
EP (1)	EP1695965B9 (pl)
JP (1)	JP4625776B2 (pl)
KR (1)	KR100827502B1 (pl)
CN (1)	CN1827600B (pl)
AP (1)	AP1907A (pl)
AR (1)	AR053147A1 (pl)
AT (1)	ATE407926T1 (pl)
BR (1)	BRPI0600623A (pl)
CA (1)	CA2537414C (pl)
CO (1)	CO5770096A1 (pl)
CR (1)	CR8248A (pl)
CU (1)	CU23614B7 (pl)
CY (1)	CY1109072T1 (pl)
DE (1)	DE602006002624D1 (pl)
DK (1)	DK1695965T3 (pl)
EA (1)	EA008464B1 (pl)
EC (2)	ECSP066373A (pl)
ES (1)	ES2313581T3 (pl)
FR (1)	FR2882553B1 (pl)
GE (1)	GEP20084465B (pl)
GT (1)	GT200600084A (pl)
HR (1)	HRP20080520T3 (pl)
IL (1)	IL173957A0 (pl)
JO (1)	JO2548B1 (pl)
MA (1)	MA28131A1 (pl)
ME (1)	ME01408B (pl)
MY (1)	MY158128A (pl)
NO (1)	NO338370B1 (pl)
NZ (1)	NZ545576A (pl)
PE (1)	PE20061009A1 (pl)
PL (1)	PL1695965T3 (pl)
PT (1)	PT1695965E (pl)
RS (1)	RS50661B (pl)
SA (1)	SA06270038B1 (pl)
SG (1)	SG125228A1 (pl)
SI (1)	SI1695965T1 (pl)
TW (1)	TWI314144B (pl)
UA (1)	UA80904C2 (pl)
UY (1)	UY29405A1 (pl)
WO (1)	WO2006092493A1 (pl)
ZA (1)	ZA200601762B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2868777B1 (fr) *	2004-04-13	2006-05-26	Servier Lab	Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) *	2005-12-21	2010-12-03	Servier Lab	Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en)	2006-11-30	2012-02-08	Cadila Healthcare Limited	Process for preparation of ivabradine hydrochloride
FR2911279B1 (fr) *	2007-01-11	2009-03-06	Servier Lab	Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
CN101353325B (zh) *	2007-07-27	2011-11-09	上海优拓医药科技有限公司	稳定型盐酸伊伐布雷定结晶及其制备方法
ES2528026T3 (es)	2007-05-30	2015-02-03	Ind-Swift Laboratories Limited	Sales de oxalato de ivabridina cristalino y polimorfos de los mismos
FR2938194B1 (fr) *	2008-11-07	2012-08-31	Servier Lab	Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe
ES2402765T3 (es)	2008-12-22	2013-05-08	Krka, D.D., Novo Mesto	Procedimiento de preparación de ivabradina
CN101774969B (zh) *	2009-01-13	2012-07-04	江苏恒瑞医药股份有限公司	硫酸伊伐布雷定及其i型结晶的制备方法
PL2902384T3 (pl)	2010-02-12	2018-04-30	Krka, D.D., Novo Mesto	Postać chlorowodorku iwabradyny
HUP1000245A2 (en)	2010-05-07	2011-11-28	Richter Gedeon Nyrt	Industrial process for the production ivabradin salts
TWI499587B (zh) *	2010-06-03	2015-09-11	Jiangsu Hengrui Medicine Co	硫酸伊伐佈雷定及其ｉ型結晶的製備方法
US8900605B2 (en)	2010-06-14	2014-12-02	Ratiopharm Gmbh	Solid ivabradine-containing composition
WO2012025940A1 (en)	2010-08-25	2012-03-01	Cadila Healthcare Limited	Polymorphic form of ivabradine hydrochloride and process for preparation thereof
CN102304088B (zh) *	2011-07-07	2013-06-19	石药集团欧意药业有限公司	一种伊伐布雷定化合物、制备方法及其药物组合物
WO2013017582A1 (en)	2011-08-02	2013-02-07	Sandoz Ag	Acetone solvate of ivabradine hydrochloride
EP2589594A1 (en)	2011-11-04	2013-05-08	Urquima S.A.	Ivabradine hydrochloride Form IV
EP2773621B1 (en)	2011-11-04	2015-12-30	Synthon BV	A process for making crystalline delta-form of ivabradine hydrochloride
WO2013102919A1 (en)	2011-11-14	2013-07-11	Cadila Healthcare Limited	Polymorphic forms of ivabradine hydrochloride
WO2014080259A1 (en) *	2012-11-21	2014-05-30	Enaltec Labs Pvt. Ltd.	Novel polymorphic forms of alcaftadine
WO2014114341A1 (en)	2013-01-24	2014-07-31	Synthon Bv	Process for making ivabradine
EP2781509B2 (en)	2013-03-19	2023-06-14	Chemo Research, S.L.	New polymorph of ivabradine hydrochloride and method for its preparation
CZ2013767A3 (cs)	2013-10-02	2015-04-29	Zentiva, K.S.	Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
MX363389B (es)	2013-12-12	2019-03-20	Synthon Bv	Composicion farmaceutica que comprende ivabradina amorfa.
SI2774606T1 (sl)	2014-02-14	2019-05-31	Synthon B.V.	Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
CZ2014478A3 (cs)	2014-07-10	2015-09-16	Zentiva, K.S.	Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en)	2014-12-22	2016-06-30	Ratiopharm Gmbh	Composition comprising ivabradine in a dissolved form
GR1008821B (el)	2015-06-11	2016-08-01	Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων	Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου
CN107056706B (zh) *	2015-12-21	2020-05-05	江苏恒瑞医药股份有限公司	一种用于制备盐酸伊伐布雷定α晶型的方法
WO2017173458A1 (en) *	2016-04-01	2017-10-05	Swiderski Cyprianna	Compositions and methods targeting hcn channels for breathing therapeutics
TR201703066A2 (tr)	2017-02-28	2018-09-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282B1 (en)	2017-02-28	2025-10-01	Sanovel Ilac Sanayi ve Ticaret A.S.	Solid oral pharmaceutical compositions of ivabradine
US20230181472A1 (en)	2018-10-30	2023-06-15	Amgen Inc.	Process of making ivabradine hydrochloride drug product
JP2023507626A (ja)	2019-12-16	2023-02-24	テナックス・セラピューティクス，インコーポレイテッド	駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
IT202000025312A1 (it)	2020-10-26	2022-04-26	Cambrex Profarmaco Milano S R L	Processi per la preparazione di polimorfi di ivabradina hcl
EP4456897A4 (en)	2021-12-31	2025-12-10	Tenax Therapeutics Inc	ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4490369A (en) *	1981-05-19	1984-12-25	Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung	Benzazepine derivatives, their pharmaceutical compositions and method of use
DE3119874A1 (de) *	1981-05-19	1982-12-09	Dr. Karl Thomae Gmbh, 7950 Biberach	"benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
AU647528B2 (en)	1990-08-29	1994-03-24	Humanetics Corporation	Treatment process for promoting weight loss employing a substituted delta5-androstene
FR2681862B1 (fr) *	1991-09-27	1993-11-12	Adir Cie	Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2818552B1 (fr)	2000-12-26	2003-02-07	Servier Lab	Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2834896B1 (fr) *	2002-01-23	2004-02-27	Servier Lab	Composition pharmaceutique orodispersible d'ivabradine
FR2868777B1 (fr) *	2004-04-13	2006-05-26	Servier Lab	Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

2005
- 2005-02-28 FR FR0501985A patent/FR2882553B1/fr not_active Expired - Fee Related
2006
- 2006-02-13 MA MA28792A patent/MA28131A1/fr unknown
- 2006-02-14 JO JO200650A patent/JO2548B1/en active
- 2006-02-14 PE PE2006000169A patent/PE20061009A1/es active IP Right Grant
- 2006-02-15 EC EC2006006373A patent/ECSP066373A/es unknown
- 2006-02-15 EC EC2006006375A patent/ECSP066375A/es unknown
- 2006-02-21 SG SG200601133A patent/SG125228A1/en unknown
- 2006-02-21 CR CR8248A patent/CR8248A/es unknown
- 2006-02-22 AP AP2006003519A patent/AP1907A/xx active
- 2006-02-22 US US11/358,954 patent/US7361649B2/en not_active Expired - Lifetime
- 2006-02-22 CU CU20060039A patent/CU23614B7/es active IP Right Grant
- 2006-02-22 TW TW095105987A patent/TWI314144B/zh active
- 2006-02-22 GT GT200600084A patent/GT200600084A/es unknown
- 2006-02-23 BR BRPI0600623-0A patent/BRPI0600623A/pt not_active Application Discontinuation
- 2006-02-24 CA CA2537414A patent/CA2537414C/fr not_active Expired - Lifetime
- 2006-02-24 UY UY29405A patent/UY29405A1/es not_active Application Discontinuation
- 2006-02-27 KR KR1020060018722A patent/KR100827502B1/ko not_active Expired - Lifetime
- 2006-02-27 UA UAA200602129A patent/UA80904C2/uk unknown
- 2006-02-27 NZ NZ545576A patent/NZ545576A/en not_active IP Right Cessation
- 2006-02-27 EA EA200600322A patent/EA008464B1/ru unknown
- 2006-02-27 SA SA06270038A patent/SA06270038B1/ar unknown
- 2006-02-27 IL IL173957A patent/IL173957A0/en active IP Right Grant
- 2006-02-27 NO NO20060946A patent/NO338370B1/no unknown
- 2006-02-27 GE GEAP20069263A patent/GEP20084465B/en unknown
- 2006-02-27 MY MYPI20060819A patent/MY158128A/en unknown
- 2006-02-28 JP JP2006051647A patent/JP4625776B2/ja not_active Expired - Lifetime
- 2006-02-28 RS RSP-2008/0551A patent/RS50661B/sr unknown
- 2006-02-28 PT PT06290326T patent/PT1695965E/pt unknown
- 2006-02-28 DE DE602006002624T patent/DE602006002624D1/de not_active Expired - Lifetime
- 2006-02-28 CO CO06019926A patent/CO5770096A1/es not_active Application Discontinuation
- 2006-02-28 CN CN2006100580765A patent/CN1827600B/zh not_active Expired - Lifetime
- 2006-02-28 AT AT06290326T patent/ATE407926T1/de active
- 2006-02-28 PL PL06290326T patent/PL1695965T3/pl unknown
- 2006-02-28 AR ARP060100728A patent/AR053147A1/es not_active Application Discontinuation
- 2006-02-28 SI SI200630111T patent/SI1695965T1/sl unknown
- 2006-02-28 ES ES06290326T patent/ES2313581T3/es not_active Expired - Lifetime
- 2006-02-28 DK DK06290326T patent/DK1695965T3/da active
- 2006-02-28 WO PCT/FR2006/000444 patent/WO2006092493A1/fr not_active Ceased
- 2006-02-28 ZA ZA200601762A patent/ZA200601762B/xx unknown
- 2006-02-28 ME MEP-2008-551A patent/ME01408B/me unknown
- 2006-02-28 EP EP06290326A patent/EP1695965B9/fr not_active Expired - Lifetime
2008
- 2008-02-26 US US12/072,461 patent/US20080161285A1/en not_active Abandoned
- 2008-09-30 CY CY20081101080T patent/CY1109072T1/el unknown
- 2008-11-27 HR HR20080520T patent/HRP20080520T3/xx unknown
2009
- 2009-10-21 US US12/589,283 patent/US7879842B2/en active Active

Also Published As

Publication number	Publication date
AP2006003519A0 (en)	2006-02-28
KR20060095501A (ko)	2006-08-31
JP2006241154A (ja)	2006-09-14
TW200640873A (en)	2006-12-01
KR100827502B1 (ko)	2008-05-06
JP4625776B2 (ja)	2011-02-02
US20080161285A1 (en)	2008-07-03
AU2006200856A1 (en)	2010-01-28
FR2882553A1 (fr)	2006-09-01
SG125228A1 (en)	2006-09-29
ECSP066373A (es)	2006-10-17
ZA200601762B (en)	2007-04-25
FR2882553B1 (fr)	2007-05-04
UY29405A1 (es)	2006-07-31
US7879842B2 (en)	2011-02-01
EP1695965B9 (fr)	2009-03-04
NZ545576A (en)	2007-01-26
ATE407926T1 (de)	2008-09-15
HRP20080520T3 (en)	2009-01-31
US20060194962A1 (en)	2006-08-31
MA28131A1 (fr)	2006-09-01
CO5770096A1 (es)	2007-06-29
AR053147A1 (es)	2007-04-25
RS50661B (sr)	2010-06-30
WO2006092493A1 (fr)	2006-09-08
US20100041640A1 (en)	2010-02-18
BRPI0600623A (pt)	2006-10-24
CA2537414C (fr)	2010-02-16
CY1109072T1 (el)	2014-07-02
CU20060039A7 (es)	2008-06-30
SI1695965T1 (sl)	2009-02-28
PT1695965E (pt)	2008-10-08
ECSP066375A (es)	2006-11-16
IL173957A0 (en)	2006-07-05
CN1827600B (zh)	2010-08-11
MY158128A (en)	2016-08-30
CR8248A (es)	2008-10-06
AP1907A (en)	2008-10-23
CN1827600A (zh)	2006-09-06
SA06270038B1 (ar)	2010-03-29
NO20060946L (no)	2006-08-29
UA80904C2 (en)	2007-11-12
CA2537414A1 (fr)	2006-08-28
TWI314144B (en)	2009-09-01
HK1096387A1 (en)	2007-06-01
ME01408B (me)	2010-06-30
GEP20084465B (en)	2008-08-25
EP1695965A1 (fr)	2006-08-30
US7361649B2 (en)	2008-04-22
CU23614B7 (es)	2011-01-27
DK1695965T3 (da)	2008-12-15
EA200600322A1 (ru)	2006-08-25
DE602006002624D1 (de)	2008-10-23
PE20061009A1 (es)	2006-11-18
ES2313581T3 (es)	2009-03-01
EA008464B1 (ru)	2007-06-29
GT200600084A (es)	2006-11-22
JO2548B1 (en)	2010-09-05
EP1695965B1 (fr)	2008-09-10
NO338370B1 (no)	2016-08-15

Publication	Publication Date	Title
SI1695965T1 (sl)	2009-02-28	Beta kristalna oblika ivabradin-hidroklorida in farmacevtski sestavki, ki jo vsebujejo
SI1707562T1 (sl)	2008-10-31	Kristalna oblika gama ivabradin-hidroklorida, postopek za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo
HUS2400009I1 (hu)	2024-06-28	Glükopiranozil-helyettesített benzonitril-származékok, ilyen vegyületeket tartalmazó gyógyászati készítmények, alkalmazásuk és elõállításukra alkalmas eljárás
SI1695709T1 (sl)	2008-10-31	Gama-d kristalna oblika hidroklorida ivabradina, postopek za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo
SI1695710T1 (sl)	2008-10-31	Kristalna oblika beta-d ivabradin-hidroklorida, postopek za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo
SI1752443T1 (sl)	2012-10-30	Nova kristalinična oblika V agomelatina, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
AP2185A (en)	2010-12-30	de, a process for its preparation and pharmaceuticDelta d crystalline form of ivabradine hydrochlorial compositions containing it.
ZA200703277B (en)	2008-06-25	Novel pyrimidine compounds, process for their preparation and compositions containing them
SI2210872T1 (sl)	2017-03-31	Nova kristalinična oblika iii agomelatina, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
IL193385A0 (en)	2009-05-04	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
IL178544A (en)	2017-04-30	Crystalline form - δ of ivabradine hydrochloride, process for preparation and pharmaceutical preparations containing it
ZA200606455B (en)	2007-12-27	Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
IL190880A (en)	2016-11-30	Crystalline posidic acid, a method of preparation and a pharmaceutical composition comprising it
ZA200706865B (en)	2008-09-25	Miocroporous crystalline material, zeolite ITQ-33, preparation method thereof and use of same
PL2231598T3 (pl)	2011-12-30	Nowe pochodne diazeniodiolanów, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
ZA200804802B (en)	2009-03-25	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
ZA200806399B (en)	2009-11-25	Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
SI1707564T1 (sl)	2007-12-31	Indanil-piperazinski derivati, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
IL203433A (en)	2016-03-31	Process for Preparing Pharmaceutical and Solid Release Controlled Compositions Containing Oxacarbazapine
IL189177A0 (en)	2008-06-05	Process for producing carcosporamide and pharmaceutical compositions containing cercosporamide
IL200951A0 (en)	2010-05-17	Aryl-sulphonamid compounds, compositions comprising the same, processes for the preparation of the same and uses thereof
ZA200807712B (en)	2010-10-27	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
HU0500126D0 (en)	2005-04-28	New compounds and process for their preparation
AP2438A (en)	2012-08-31	Pharmaceutical composition suitable for the treatment of malaria within one day
SI1879869T1 (sl)	2009-06-30	Postopek za pripravo prekurzorjev 5-alkiltioalkilamino-1-fenil-pirazolov